Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

Length and width, not thickness, emerge as key drivers of higher-order aberrations.

A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.